Clinical Trial Detail

NCT ID NCT02567435
Title Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

embryonal rhabdomyosarcoma

rhabdomyosarcoma

alveolar rhabdomyosarcoma

Therapies

Cyclophosphamide + Dactinomycin + Vincristine Sulfate

Temsirolimus

Irinotecan

Age Groups: child adult

No variant requirements are available.